Managing 'resistance': Is adherence a target for treatment?

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 5, 2014, Pages 439-443

  Burnier, Michel ^a  

^a Service of Nephrology   (Switzerland)

Author keywords

adherence; drug; hypertension; monitoring

Indexed keywords

ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE REGULATION; HUMAN; MEDICATION COMPLIANCE; NONHUMAN; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; RESISTANT HYPERTENSION; REVIEW; TREATMENT RESPONSE; BLOOD PRESSURE; DRUG EFFECTS; DRUG RESISTANCE; HYPERTENSION; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG RESISTANCE; HUMANS; HYPERTENSION; MEDICATION ADHERENCE; TREATMENT OUTCOME;

EID: 84906096111     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000045     Document Type: Review

References (21)

1. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125: 1635-1642.
2. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
3. Calhoun DA, Booth JN 3rd, Oparil S, et al. Refractory hypertension: Determination of prevalence, risk factors, and comorbidities in a large, populationbased cohort. Hypertension 2014; 63:451-458.
4. Savard S, Frank M, Bobrie G, et al. Eligibility for renal denervation in patients with resistant hypertension: When enthusiasm meets reality in real-life patients. J Am Coll Cardiol 2012; 60:2422-2424.
5. Persu A, Jin Y, Baelen M, et al., European Network Coordinating research on REnal Denervation (ENCOReD) Consortium. Eligibility for renal denervation: Experience at 11 European expert centers. Hypertension 2014; 63:1319-1325.
6. De La Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57:898-902.
7. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57:1076-1080.
8. Burnier M, Schneider MP, Chiolero A, et al. Electronic compliance monitoring in resistant hypertension: The basis for rational therapeutic decisions. J Hypertens 2001; 19:335-341.
9. Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31:766-774.
10. Fadl Elmula FE, Hoffmann P, Larstorp AC, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatmentresistant hypertension. Hypertension 2014; 63:991-999.
11. Vrijens B, De Geest S, Hughes DA, et al., ABC Project Team. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 2012; 73:691-705.
12. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: Longitudinal study of electronically compiled dosing histories. BMJ 2008; 336:1114-1117.
13. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: Meta-Analysis on 376,162 patients. Am J Med 2012; 125:882-887.
14. Burnier M, Brede Y, Lowy A. Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: Comparison of aliskiren, irbesartan and ramipril. Int J Clin Pract 2011; 65:127-133.
15. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med 1990; 150:1509-1510.
16. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-Analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333:15.
17. Christensen A, Osterberg LG, Hansen EH. Electronic monitoring of patient adherence to oral antihypertensive medical treatment: A systematic review. J Hypertens 2009; 27:1540-1551.
18. Wetzels GE, Nelemans PJ, Schouten JS, et al. Electronic monitoring of adherence as a tool to improve blood pressure control. A randomized controlled trial. Am J Hypertens 2007; 20:119-125.
19. Corrao G, Parodi A, Nicotra F, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29:610-618.
20. Granger BB, Swedberg K, Ekman I, et al., CHARM investigators. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: Double-blind, randomised, controlled clinical trial. Lancet 2005; 366:2005-2011.
21. Santschi V, Chiolero A, Burnand B, et al. Impact of pharmacist care in the management of cardiovascular disease risk factors: A systematic review and meta-Analysis of randomized trials. Arch Intern Med 2011; 171:1441-1453.